← back to search

Miriam Freimer

The Ohio State University · US
Area of research
Neurology · Oncology
Research interest
Research interests include Medicine, Myasthenia gravis, Placebo, Tolerability, Internal medicine, and Eculizumab.
h-index
citations
1,012
works
12
NIH funding
primary concept
email

Recent publications

Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial
The Lancet Neurology 2024cited by 34position: middledoi
104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07)
Journal of Neurology 2024cited by 24position: middledoi
Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial
The Lancet Neurology 2023cited by 34position: middledoi
Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay
Amyloid 2023cited by 14position: middledoi
Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: a genome-wide association study
Proceedings of the National Academy of Sciences 2022cited by 128position: middledoi
Development of a standard of care for patients with valosin-containing protein associated multisystem proteinopathy
Orphanet Journal of Rare Diseases 2022cited by 35position: middledoi
Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis
JAMA Neurology 2020cited by 192position: middledoi
Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North America
BMJ Open 2020cited by 20position: middledoi
A Genome-Wide Association Study of Myasthenia Gravis
JAMA Neurology 2015cited by 220position: middledoi
A randomized, double‐blind, placebo‐controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis
Muscle & Nerve 2013cited by 224position: middledoi
SMA valiant trial: A prospective, double‐blind, placebo‐controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy
Muscle & Nerve 2013cited by 76position: middledoi
Randomized, Double-Blind, Placebo-Controlled, Crossover, Multicenter, Phase II Study of Eculizumab in Patients with Refractory Generalized Myasthenia Gravis (gMG) (S35.004)
Neurology 2012cited by 11position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Michael Benatar · University of Miami2 papers (2012–2013)James F. Howard · University of North Carolina at Chapel Hill2 papers (2012–2013)Richard J. Barohn · Virginia Commonwealth University2 papers (2012–2013)Vern C. Juel · Duke University2 papers (2012–2013)Tahseen Mozaffar · University of California, Irvine2 papers (2012–2013)Michelle Mellion · Brown University2 papers (2012–2013)Maria Elena Farrugia · University of Glasgow2 papers (2012–2013)John T. Kissel · The Ohio State University Wexner Medical Center2 papers (2013–2013) · 1 papers (2013–2013)Bakri Elsheikh · The Ohio State University Wexner Medical Center1 papers (2013–2013)Thomas O. Crawford · Johns Hopkins University1 papers (2013–2013) · 1 papers (2013–2013)Kristin J. Krosschell · Eunice Kennedy Shriver National Institute of Child Health and Human Development1 papers (2013–2013)Charles Scott · Queen's University1 papers (2013–2013)Gary Cutter · Epilepsy Foundation1 papers (2013–2013)Stephen J. Kolb · University of Iowa1 papers (2013–2013)Gyula Acsádi · University of Colorado Denver1 papers (2013–2013)Louise R. Simard · University of Manitoba1 papers (2013–2013)Sandra P. Reyna · Novartis (Switzerland)1 papers (2013–2013) · 1 papers (2013–2013)